Bharat Biotech has claimed that among all vaccine platforms like an mRNA-based vaccine, a DNA-based vaccine, a vector-based vaccine or live attenuated vaccines, etc., the inactivated vaccines developed by Covat 19 are the safest and therefore the side effects are less.
In a series of frequently asked questions (FAQs) about its studies, Bharat Biotech said BBV-152 was a full virion inactivated SARS-CoV-2 vaccine. Among all the vaccine platforms such as an mRNA-based vaccine, a DNA-based vaccine, a vector-based vaccine or live attenuated vaccines, etc., the inactivated vaccines are the safest and therefore the side effects are less.
It is said that approximately 755 participants were vaccinated in Phase 1 and 2 clinical trials. No serious adverse events related to the vaccine were reported in Phase 1 and 2 clinical trials.
The vaccination with BBV-152B could only protect the participants 14 days after the second vaccination dose. Therefore, participants should take the following precautions to avoid SARSCoV-2 infection for up to 14 days after the second dose of vaccine.
Because participants will be vaccinated before the results of the RT-PCR and ELISA tests are known, there is a chance that participants with asymptomatic SARS-CoV-2 infection could enter the study and later show symptoms of Covid-19.
In addition, participants who were recently infected with SARS-CoV-2 before the first vaccination dose and have a viral load below the detection limit (LoD) of the RTPCR test kit may not be able to be detected by RT-PCR later show the Covid-19- Symptoms.
Since there is also an equal chance of getting a placebo for each participant, 50 percent of the participants will get the placebo, and they can get SARS-CoV-2 infection / Covid-19 anytime after vaccination.
Bharat Biotech said that if there was a successful demonstration of efficacy determined during the interim analysis, participants who received a placebo could receive a vaccination at the end of the study after receiving approval from regulators.
It is said that frontline workers are given vaccines when a vaccine is first approved. Older people take at least 6 months (more than 65 years to receive the vaccine).
Due to the limited supply, it will take at least 6 to 12 months for a person under 60 to receive a vaccine.
“If you are in this study, it will most likely get this vaccine approved within a few months. If you have received a placebo, we will contact you and give you the vaccine so that priority access to the vaccine (even if you are under 60) is given Years) “, it said.
san / rs
(Only the headline and image of this report may have been updated by Business Standard staff. The rest of the content is automatically generated from a syndicated feed.)